Search Results - "Dearden, Claire E."

Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial by GONZALEZ, David, MARTINEZ, Pilar, WADE, Rachel, HOCKLEY, Sarah, OSCIER, David, MATUTES, Estella, DEARDEN, Claire E, RICHARDS, Sue M, CATOVSKY, Daniel, MORGAN, Gareth J

“…TP53 mutations have been described in chronic lymphocytic leukemia (CLL) and have been associated with poor prognosis in retrospective studies. We aimed to…”
Get full text

Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial by PETTITT, Andrew R, JACKSON, Richard, CATOVSKY, Daniel, RADFORD, John A, BLOOR, Adrian, FOLLOWS, George A, DEVEREUX, Stephen, KRUGER, Anton, BLUNDELL, Julie, AGRAWAL, Samir, ALLSUP, David, PROCTOR, Stephen, CARRUTHERS, Stacey, HEARTIN, Earnest, OSCIER, David, HAMBLIN, Terry J, RAWSTRON, Andrew, HILLMEN, Peter, DODD, James, DODD, Susanna, OATES, Melanie, JOHNSON, Gillian G, SCHUH, Anna, MATUTES, Estella, DEARDEN, Claire E

“…In chronic lymphocytic leukemia (CLL), TP53 deletion/mutation is strongly associated with an adverse outcome and resistance to chemotherapy-based treatment. In…”
Get full text

Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma by Else, Monica, Marín-Niebla, Ana, de la Cruz, Fátima, Batty, Paul, Ríos, Eduardo, Dearden, Claire E., Catovsky, Daniel, Matutes, Estella

“…Summary Splenic marginal zone lymphoma (SMZL) is a rare B‐cell malignancy, with no standard treatment other than splenectomy. Rituximab has shown encouraging…”
Get full text

The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience by Sriskandarajah, Priya, Pawlyn, Charlotte, Mohammed, Kabir, Dearden, Claire E., Davies, Faith E., Morgan, Gareth J., Boyd, Kevin D., Kaiser, Martin F.

Get full text

Long-term follow-up after purine analogue therapy in hairy cell leukaemia by Else, Monica, Dearden, Claire E, Catovsky, Daniel

“…Abstract Since 2006 when we last reviewed the literature concerning the use of purine analogues in hairy cell leukaemia (HCL), results from several new and…”
Get full text

Epidemiology and Environmental Aspects of Marginal Zone Lymphomas by Sriskandarajah, Priya, MBBS, BSc, MRCP, Dearden, Claire E

“…Abstract Marginal zone lymphomas (MZLs) account for between 5% and 17% of all non-hodgkin’s lymphomas. MZLs consist of 3 different subtypes with extranodal…”
Get full text

Guidelines for the management of mature T‐cell and NK‐cell neoplasms (excluding cutaneous T‐cell lymphoma) by Dearden, Claire E., Johnson, Rod, Pettengell, Ruth, Devereux, Stephen, Cwynarski, Kate, Whittaker, Sean, McMillan, Andrew

“…Summary The peripheral T‐cell neoplasms are a biologically and clinically heterogeneous group of rare disorders that result from clonal proliferation of mature…”
Get full text

Long-term results for pentostatin and cladribine treatment of hairy cell leukemia by Dearden, Claire E., Else, Monica, Catovsky, Daniel

“…Over the past 25 years we have collected data at our institution from 242 patients with hairy cell leukemia (HCL), treated with pentostatin (n = 188) or…”
Get full text

Ocular and cerebral aspergillosis in a non-neutropenic patient following alemtuzumab and methyl prednisolone treatment for chronic lymphocytic leukaemia by Anoop, Parameswaran, Saso, Radovan, Dearden, Claire E, Stanford, Miles

Get full text

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study by HILLMEN, Peter, GRIBBEN, John G, NATHWANI, Amit, VARGHESE, Abraham, COHEN, Dena, RAWSTRON, Andy, OERTEL, Stephan, POCOCK, Christopher F. E, FOLLOWS, George A, MILLIGAN, Donald, SAYALA, Hazem A, MORETON, Paul, OSCIER, David G, DEARDEN, Claire E, KENNEDY, Daniel B, PETTITT, Andrew R

“…Most patients with chronic lymphocytic leukemia (CLL) are elderly and/or have comorbidities that may make them ineligible for fludarabine-based treatment. For…”
Get full text

Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route by Dearden, Claire E., Khot, Amit, Else, Monica, Hamblin, Mike, Grand, Effie, Roy, Ashok, Hewamana, Saman, Matutes, Estella, Catovsky, Daniel

“…Intravenous alemtuzumab is an effective and well-tolerated treatment for T-cell prolymphocytic leukemia (T-PLL). Alemtuzumab given intravenously as first-line…”
Get full text

Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline by Schuh, Anna H, Parry-Jones, Nilima, Appleby, Niamh, Bloor, Adrian, Dearden, Claire E, Fegan, Christopher, Follows, George, Fox, Christopher P, Iyengar, Sunil, Kennedy, Ben, McCarthy, Helen, Parry, Helen M, Patten, Piers, Pettitt, Andrew R, Ringshausen, Ingo, Walewska, Renata, Hillmen, Peter

Get full text

Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis by Else, Monica, Dearden, Claire E., Matutes, Estella, Garcia‐Talavera, Juan, Rohatiner, Ama Z. S., Johnson, Steve A. N., O’Connor, Nigel T. J., Haynes, Andy, Osuji, Nnenna, Forconi, Francesco, Lauria, Francesco, Catovsky, Daniel

“…Summary Hairy cell leukaemia (HCL) was first described 50 years ago. Median survival was then 4 years. The purine analogues, introduced in the 1980s,…”
Get full text

An unusual indication for splenectomy in hairy cell leukaemia: a report of three cases with persistent splenomegaly after chemoimmunotherapy by Sarid, Nadav, Ahmad, Humayun N, Wotherspoon, Andrew, Dearden, Claire E, Else, Monica, Catovsky, Daniel

“…Summary We describe three cases of relapsed hairy cell leukaemia (HCL) treated with pentostatin plus rituximab. All three achieved bone marrow complete…”
Get full text

Stem cell transplantation after alemtuzumab in T‐cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study by Krishnan, Biju, Else, Monica, Tjonnfjord, Geir E., Cazin, Bruno, Carney, Dennis, Carter, John, Ketterer, Nicolas, Catovsky, Daniel, Ethell, Mark, Matutes, Estella, Dearden, Claire E.

Get full text

Guideline for the treatment of chronic lymphocytic leukaemia by Schuh, Anna H., Parry‐Jones, Nilima, Appleby, Niamh, Bloor, Adrian, Dearden, Claire E., Fegan, Christopher, Follows, George, Fox, Christopher P., Iyengar, Sunil, Kennedy, Ben, McCarthy, Helen, Parry, Helen M., Patten, Piers, Pettitt, Andrew R., Ringshausen, Ingo, Walewska, Renata, Hillmen, Peter

Get full text

Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta by Apperley, Jane F, Gardembas, Martine, Melo, Junia V, Russell-Jones, Robin, Bain, Barbara J, Baxter, E. Joanna, Chase, Andrew, Chessells, Judith M, Colombat, Marie, Dearden, Claire E, Dimitrijevic, Sasa, Mahon, François-X, Marin, David, Nikolova, Zariana, Olavarria, Eduardo, Silberman, Sandra, Schultheis, Beate, Cross, Nicholas C.P, Goldman, John M

“…Imatinib mesylate blocks the activity of three protein tyrosine kinases: ABL, KIT, and platelet-derived growth factor receptor β (PDGFRB). These kinases have…”
Get full text

Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence by Else, Monica, Dearden, Claire E., Matutes, Estella, Forconi, Francesco, Lauria, Francesco, Ahmad, Humayun, Kelly, Susan, Liyanage, Anandika, Ratnayake, Vijitha, Shankari, Jagadeesan, Whalley, Ioana, Catovsky, Daniel

“…The purine analogs pentostatin and cladribine are effective treatments for hairy cell leukemia (HCL). However, alternative treatments are needed for patients…”
Get full text

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial by Dearden, Claire E., Richards, Sue, Else, Monica, Catovsky, Daniel, Hillmen, Peter

“…BACKGROUND: An oral formulation of fludarabine was introduced for use in chronic lymphocytic leukemia in 2001 following studies demonstrating the…”
Get full text

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H by Dearden, Claire E., Matutes, Estella, Cazin, Bruno, Tjønnfjord, Geir E., Parreira, Antonio, Nomdedeu, Benet, Leoni, Pietro, Clark, Fiona J., Radia, Deepti, Rassam, Saad M.B., Roques, Tony, Ketterer, Nicolas, Brito-Babapulle, Vasantha, Dyer, Martin J.S., Catovsky, Daniel

“…T-cell prolymphocytic leukemia (T-PLL) is a chemotherapy-resistant malignancy with a median survival of 7.5 months. Preliminary results indicated a high…”
Get full text